Normal view
-
TechCrunch
-
AI research startup Listen Labs scrubbed a $1.5B funding round for Salesforce talks
Listen Labs walked away from a signed Series C term sheet from Menlo Ventures, sources say.
-
STAT

-
STAT+: Orexin discoverers awarded prestigious Lasker award
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. First came the new teaser for Nathan Fielder’s documentary on Elizabeth Holmes. Now come the memes. Bring it on. FDA names permanent heads of drug and biologics centers For the past few months, key centers at the FDA have been led by acting officials. The agency said yesterday it will now make them permanent. Michael Davis will be director of the Center for Drug Ev
STAT+: Orexin discoverers awarded prestigious Lasker award
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
First came the new teaser for Nathan Fielder’s documentary on Elizabeth Holmes. Now come the memes. Bring it on.
FDA names permanent heads of drug and biologics centers
For the past few months, key centers at the FDA have been led by acting officials. The agency said yesterday it will now make them permanent. Michael Davis will be director of the Center for Drug Evaluation and Research, and Karim Mikhail will be director of the Center for Biologics Evaluation and Research.
Continue to STAT+ to read the full story…


© Adobe
-
STAT

-
STAT+: FDA approves AstraZeneca breast cancer drug
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we delve into how an FDA approval paradoxically complicated access to Revolution Medicines’ new pancreatic cancer drug for some patients, see standout mid-stage results for Roivant’s pulmonary hypertension drug, and more. Hope you had a lovely long weekend! Estoy trabajando en este Readout de la Biblioteca Vasconcelos en la CDMX.Continue to STAT+ to read the fu
STAT+: FDA approves AstraZeneca breast cancer drug
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we delve into how an FDA approval paradoxically complicated access to Revolution Medicines’ new pancreatic cancer drug for some patients, see standout mid-stage results for Roivant’s pulmonary hypertension drug, and more.
Hope you had a lovely long weekend! Estoy trabajando en este Readout de la Biblioteca Vasconcelos en la CDMX.
Continue to STAT+ to read the full story…


© ANDREW YATES/AFP via Getty Images